A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus

Abstract Nipah and Hendra viruses are highly pathogenic bat-borne paramyxoviruses recently included in the WHO Blueprint priority diseases list. A fully registered horse anti-Hendra virus subunit vaccine has been in use in Australia since 2012. Based on the same immunogen, the Hendra virus attachmen...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Thomas W. Geisbert, Kathryn Bobb, Viktoriya Borisevich, Joan B. Geisbert, Krystle N. Agans, Robert W. Cross, Abhishek N. Prasad, Karla A. Fenton, Hao Yu, Timothy R. Fouts, Christopher C. Broder, Antony S. Dimitrov
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/652276c0d46b42ed8977b0d8d12fab81
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:652276c0d46b42ed8977b0d8d12fab81
record_format	dspace
spelling	oai:doaj.org-article:652276c0d46b42ed8977b0d8d12fab812021-12-02T12:09:18ZA single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus10.1038/s41541-021-00284-w2059-0105https://doaj.org/article/652276c0d46b42ed8977b0d8d12fab812021-02-01T00:00:00Zhttps://doi.org/10.1038/s41541-021-00284-whttps://doaj.org/toc/2059-0105Abstract Nipah and Hendra viruses are highly pathogenic bat-borne paramyxoviruses recently included in the WHO Blueprint priority diseases list. A fully registered horse anti-Hendra virus subunit vaccine has been in use in Australia since 2012. Based on the same immunogen, the Hendra virus attachment glycoprotein ectodomain, a subunit vaccine formulation for use in people is now in a Phase I clinical trial. We report that a single dose vaccination regimen of this human vaccine formulation protects against otherwise lethal challenges of either Hendra or Nipah virus in a nonhuman primate model. The protection against the Nipah Bangladesh strain begins as soon as 7 days post immunization with low dose of 0.1 mg protein subunit. Our data suggest this human vaccine could be utilized as efficient emergency vaccine to disrupt potential spreading of Nipah disease in an outbreak setting.Thomas W. GeisbertKathryn BobbViktoriya BorisevichJoan B. GeisbertKrystle N. AgansRobert W. CrossAbhishek N. PrasadKarla A. FentonHao YuTimothy R. FoutsChristopher C. BroderAntony S. DimitrovNature PortfolioarticleImmunologic diseases. AllergyRC581-607Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Vaccines, Vol 6, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Thomas W. Geisbert Kathryn Bobb Viktoriya Borisevich Joan B. Geisbert Krystle N. Agans Robert W. Cross Abhishek N. Prasad Karla A. Fenton Hao Yu Timothy R. Fouts Christopher C. Broder Antony S. Dimitrov A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus
description	Abstract Nipah and Hendra viruses are highly pathogenic bat-borne paramyxoviruses recently included in the WHO Blueprint priority diseases list. A fully registered horse anti-Hendra virus subunit vaccine has been in use in Australia since 2012. Based on the same immunogen, the Hendra virus attachment glycoprotein ectodomain, a subunit vaccine formulation for use in people is now in a Phase I clinical trial. We report that a single dose vaccination regimen of this human vaccine formulation protects against otherwise lethal challenges of either Hendra or Nipah virus in a nonhuman primate model. The protection against the Nipah Bangladesh strain begins as soon as 7 days post immunization with low dose of 0.1 mg protein subunit. Our data suggest this human vaccine could be utilized as efficient emergency vaccine to disrupt potential spreading of Nipah disease in an outbreak setting.
format	article
author	Thomas W. Geisbert Kathryn Bobb Viktoriya Borisevich Joan B. Geisbert Krystle N. Agans Robert W. Cross Abhishek N. Prasad Karla A. Fenton Hao Yu Timothy R. Fouts Christopher C. Broder Antony S. Dimitrov
author_facet	Thomas W. Geisbert Kathryn Bobb Viktoriya Borisevich Joan B. Geisbert Krystle N. Agans Robert W. Cross Abhishek N. Prasad Karla A. Fenton Hao Yu Timothy R. Fouts Christopher C. Broder Antony S. Dimitrov
author_sort	Thomas W. Geisbert
title	A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus
title_short	A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus
title_full	A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus
title_fullStr	A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus
title_full_unstemmed	A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus
title_sort	single dose investigational subunit vaccine for human use against nipah virus and hendra virus
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/652276c0d46b42ed8977b0d8d12fab81
work_keys_str_mv	AT thomaswgeisbert asingledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT kathrynbobb asingledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT viktoriyaborisevich asingledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT joanbgeisbert asingledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT krystlenagans asingledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT robertwcross asingledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT abhisheknprasad asingledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT karlaafenton asingledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT haoyu asingledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT timothyrfouts asingledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT christophercbroder asingledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT antonysdimitrov asingledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT thomaswgeisbert singledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT kathrynbobb singledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT viktoriyaborisevich singledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT joanbgeisbert singledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT krystlenagans singledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT robertwcross singledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT abhisheknprasad singledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT karlaafenton singledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT haoyu singledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT timothyrfouts singledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT christophercbroder singledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus AT antonysdimitrov singledoseinvestigationalsubunitvaccineforhumanuseagainstnipahvirusandhendravirus
_version_	1718394693795971072

A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus

Ejemplares similares